Based on these findings, we suggest that 6-shogaol + gefitinib co-treatment may overcome EGFR-mediated resistance and induce a programmed cell death pathway via the excessive ER stress response in ovarian cancer cells and gefitinib-resistant cancer cells. The gene discussed is EGFR; the disease is ovarian cancer.